Cognition Therapeutics Reports Dosing O First Patient In MAGNIFY Study Of Oral CT1812 For Geographic Atrophy Secondary To Dry AMD
Portfolio Pulse from Benzinga Newsdesk
Cognition Therapeutics has begun dosing the first patient in its MAGNIFY study of oral CT1812 for Geographic Atrophy secondary to Dry AMD. The study is a randomized, placebo-controlled trial expected to enroll around 246 adults diagnosed with dry AMD with measurable GA.
July 11, 2023 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cognition Therapeutics has started dosing in its MAGNIFY study, which could potentially lead to a new treatment for dry AMD. This could have a positive impact on the company's stock if the trial results are positive.
The initiation of dosing in a clinical trial is a significant milestone for any biotech company. If the trial results are positive, it could lead to a new treatment option for dry AMD, potentially boosting the company's revenues and positively impacting the stock price. However, the final impact will depend on the trial results, which are yet to be known.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100